Ivermectin and permethrin are both considered in the treatment of scabies, an infestation caused by the human itch mite, but they are different medicines with different ways of being used. In the United States, permethrin cream 5% is a prescription topical scabies treatment with an FDA-approved indication. Human oral ivermectin tablets are also prescription products, but their use for scabies is off-label: the tablets are FDA-approved for certain parasitic worm infections, not specifically for scabies. These distinctions matter when comparing pharmacy listings, medical recommendations and the meaning of an approved product label.
For ordinary (classic) scabies, CDC clinical guidance identifies permethrin cream 5% and oral ivermectin as treatment options and reports similar effectiveness for cure under studied conditions. That statement does not establish that one medicine will work better for every person. Applying a medicine to the skin and swallowing prescription tablets involve different practical steps, contraindications and reasons for clinician follow-up. Age, pregnancy status, medication interactions, the ability to complete an application correctly and the possibility of more complicated scabies can all affect the treatment decision. Neither approach should be selected solely on the basis of a commercial product listing.
This page provides a side-by-side interpretation of the two scabies options rather than an individual treatment plan. Readers who want a condition-focused discussion can visit ivermectin for scabies; those researching the tablet product category can review oral ivermectin products. The sections below explain FDA status, route of administration, safety considerations, pharmacy access and what questions are useful before a prescription is filled. Treatment instructions, including any repeat treatment, must come from the treating clinician and the specific medication label.
The comparison must specify the formulations. For scabies, the relevant permethrin product is prescription cream 5%, not over-the-counter permethrin 1% head-lice products. The ivermectin side of the comparison is human oral tablets, not ivermectin cream 1% for rosacea or ivermectin lotion 0.5% for head lice. Similar ingredient or product names do not make those formulations appropriate substitutes. Both scabies approaches require an individualized medical decision and a clear understanding of what has actually been prescribed.
The FDA-status distinction is especially important. Permethrin cream 5% has an approved scabies indication; oral ivermectin use for scabies is a clinician-directed off-label use. Off-label prescribing can be lawful and medically appropriate, but it does not change the FDA-approved indications shown on a drug label. CDC treatment guidance addresses both options, while product labels and patient-specific clinical circumstances still govern what a pharmacy can dispense and how a patient should use it.
| Comparison point | Oral ivermectin tablets | Permethrin cream 5% |
|---|---|---|
| Active ingredient | Ivermectin | Permethrin |
| Product type | Human-use oral prescription tablets | Topical prescription cream for skin use |
| FDA approval for scabies | No; use for scabies is off-label | Yes; scabies is a labeled indication |
| Relevant route | Swallowed as directed by a clinician | Applied to the skin according to the prescription label |
| FDA-labeled indication context | Certain parasitic worm infections, not scabies | Scabies caused by Sarcoptes scabiei |
| Pediatric considerations | Safety for children weighing less than 15 kg is not established in CDC guidance | FDA-approved for scabies from 2 months of age |
| Pregnancy considerations | Safety data are limited; clinician assessment is essential | Clinician assesses suitability and label precautions |
| Prescription requirement | Prescription (Rx) | Prescription (Rx) |
| Treatment completion | Repeat dosing or other steps depend on the prescribed regimen | Coverage of the prescribed skin areas and any repeat application depend on clinical directions |
| Not interchangeable with | Veterinary products, rosacea cream or lice lotion | OTC permethrin 1% lice formulations |
Scabies is a skin infestation involving Sarcoptes scabiei mites. Itching and a characteristic rash can prompt clinical evaluation, but other conditions can look similar. A diagnosis may depend on the pattern of symptoms, contact history and examination; it should not be inferred simply because a person sees an antiparasitic medicine for sale. The difference between a suspected and a confirmed infestation matters because inappropriate treatment may delay care for the actual cause of symptoms.
Product terminology creates another common source of confusion. Permethrin is sold in more than one formulation, including a 1% head-lice treatment and prescription 5% scabies cream. Ivermectin likewise appears in oral tablets, prescription facial cream and OTC lice lotion. The fact that a medicine treats one type of infestation does not prove that its other formulation is indicated for scabies. For a separate lice-specific comparison, see ivermectin lotion versus permethrin for head lice.
A clinician may also distinguish classic scabies from crusted scabies, a more severe condition that requires a different management approach. No commercial comparison should suggest that one generic product or one route is always appropriate for every presentation. If symptoms are severe, extensive, recurring or accompanied by diagnostic uncertainty, the relevant next step is medical assessment rather than experimenting with products from another category. This page compares treatment types without identifying a particular person’s condition.
Permethrin is a synthetic pyrethroid that acts on parasite nerve function. In the U.S., permethrin cream 5% is approved for treating scabies, and CDC lists it among first-line options for classic scabies. The product is applied to the skin rather than taken by mouth. Its labeled age range begins at 2 months, but that age threshold should not be converted into advice that every child with a rash can use the cream without assessment. Instructions about the areas to cover, time on the skin and follow-up are specific to the product and patient.
The practical challenge of a topical scabies treatment is correct application. Missing skin areas, washing the product away prematurely or misunderstanding whether a repeat application is required can complicate the treatment process. Infants, older adults and people with particular skin or health circumstances may need instructions that differ from a general summary. A person should use the directions supplied with the specific prescription rather than extrapolating from an over-the-counter 1% lice product, a rosacea cream or a general website checklist.
Topical treatment also has its own tolerability questions. Stinging, burning, itching or skin irritation can occur, and scabies itself causes intense inflammation and itching. Persistent discomfort after treatment does not automatically establish treatment failure or an allergy. A clinician can review the timing of symptoms, visible skin changes and possible reinfestation before deciding whether more treatment or a different diagnosis should be considered. In this comparison, permethrin 5% is evaluated as a prescription scabies formulation, not a universal remedy for unexplained skin irritation.
Human oral ivermectin tablets are FDA-approved for selected parasitic worm infections. Using them to treat scabies is therefore off-label in the United States, even though CDC clinical guidance includes oral ivermectin among options for classic scabies. This distinction should be made visible wherever tablets are compared with permethrin cream 5%. An off-label prescription is a clinical decision made after evaluation; it is not permission for a retailer to sell a prescription medicine without a valid prescription or for a patient to choose a treatment schedule independently.
A clinician may consider oral administration in situations where correctly applying a topical medicine is difficult, but there is no one-factor rule determining the better route. Before prescribing, the clinician must consider the patient’s diagnosis, medication list, pregnancy or breastfeeding circumstances, weight-related pediatric precautions and whether a different treatment approach is indicated. CDC notes that safety has not been established for children weighing less than 15 kg or for pregnant women in the context of oral ivermectin for scabies. These issues cannot be addressed merely by choosing a particular tablet strength.
U.S. tablets are identified by product labels and prescription details, not by the scabies search term in an online advertisement. The 3 mg tablet guide and 6 mg tablet guide cover strength-specific identity and labeling. Neither tablet-strength page is a personal dosing recommendation, and FDA approval of a human tablet strength does not establish its current stock at any pharmacy. Questions about whether off-label use is appropriate belong with the prescribing clinician.
CDC describes oral ivermectin and permethrin 5% cream as having similar efficacy for curing classic scabies in the evidence it summarizes. That is a useful comparative statement, but it is not a guarantee of cure for an individual patient. Studies can differ in who was enrolled, how treatment success was defined, the timing of assessment and the prescribed course. Apparent differences may also depend on whether applications or medicine administration were completed as directed and whether continuing exposure led to reinfestation.
The drugs act differently: permethrin is applied directly to the skin as a scabicide, while ivermectin is administered systemically as an oral medicine. The route determines practical responsibilities but does not, by itself, prove superior efficacy. A patient who can apply topical treatment correctly may face different considerations from someone who has difficulty reaching or covering affected areas. Clinicians also need to distinguish persistent itching after an effective treatment from evidence that mites remain active. Neither a higher-strength label nor a shorter-looking commercial regimen is reliable proof of better results.
It is also important not to extrapolate from other ivermectin uses. Studies involving ivermectin lotion for head lice, ivermectin cream for rosacea or oral tablets for other parasitic infections do not constitute a head-to-head scabies trial against permethrin 5% cream. Similarly, results for crusted scabies cannot be treated as though they describe routine classic scabies. For broader clinical context, see the dedicated discussion of ivermectin use in scabies; the evidence on this page remains focused on comparison with permethrin 5% cream.
A prescription for topical permethrin comes with instructions about which skin areas to treat and when the product should be removed. Oral ivermectin comes with oral administration instructions and a clinician-defined treatment schedule. These are not equivalent tasks. Someone evaluating the options may want to tell a clinician about mobility, the availability of help applying a cream, the presence of irritated skin, the ability to follow the written directions and any constraints around a return visit. Those are legitimate factors in a treatment discussion, not grounds for substituting one medicine without authorization.
Repeat treatment is another area where a high-level comparison can be misleading. Permethrin may require another application in some circumstances, and CDC describes repeat oral ivermectin dosing in its scabies guidance. The timing and need for any repeat treatment are medical decisions dependent on the prescribed regimen. Patients should not use the appearance of an online product listing, the amount in a package or a friend’s regimen to determine whether another application or oral dose is necessary.
A useful pre-visit discussion also covers what constitutes evidence of treatment success and when to return for reassessment. Itching may remain after mites are eliminated, while new burrows or a worsening rash can indicate a different concern. The clinician may advise follow-up when symptoms persist, recur or occur among close contacts. A written plan for both medication use and follow-up reduces confusion between a treatment that was not completed as directed and true lack of response.
Neither medicine should be chosen without considering the patient. Permethrin cream 5% is FDA-approved for scabies from 2 months of age, but product instructions still address contraindications and possible skin reactions. Oral ivermectin raises different questions, including systemic exposure, other medicines, pregnancy status and weight-related concerns in children. CDC notes limited safety information for oral ivermectin in certain groups; a clinician weighs those uncertainties against the condition being treated. The lower age limit on a topical product cannot be carried over to a tablet.
Patients should disclose prescription medicines, nonprescription products, supplements, allergies and relevant health conditions to the prescribing clinician or pharmacist. For topical permethrin, a history of hypersensitivity to the product or certain related compounds requires attention; for oral ivermectin, other medications and clinical circumstances can affect suitability. No online comparison can reliably screen for interactions or recommend discontinuing existing therapy. Additional context on general ivermectin precautions is available in the ivermectin safety overview.
Pregnancy and breastfeeding questions warrant individualized discussion rather than blanket reassurance. Safety evidence, route of administration and the need for scabies treatment must be assessed together. Animal ivermectin preparations are not substitutes for human oral tablets, and an OTC head-lice treatment is not a safe workaround for obtaining a scabies product. A pharmacist can help identify the dispensed product, but treatment selection and changes to a prescribed regimen remain clinical decisions.
Classic scabies and crusted scabies cannot be managed as interchangeable categories. Crusted scabies is a more severe, highly contagious presentation that often calls for specialist-guided combination therapy rather than simply choosing between one cream and one oral tablet. CDC describes approaches combining oral ivermectin with topical scabicides for crusted scabies. This page does not reproduce those complex schedules because they belong in specialist care, where diagnosis, disease severity and other medical conditions determine the plan.
Treating the affected person is only part of managing an infestation. Household members and other close contacts may need evaluation or coordinated treatment, and guidance about cleaning clothing, towels and bedding can help reduce ongoing exposure. The relevant advice differs from cleaning routines used for head lice or other skin conditions. If the same contacts remain untreated or the exposure setting has not been addressed, symptoms may reappear even after a properly selected medication. Environmental measures should follow public-health and clinician guidance rather than commercial claims that a special household pesticide is required.
Itching can persist for a period after successful scabies treatment because the skin continues to react to the infestation. Persistent itching alone is not proof of resistant mites, and automatically repeating medication may be inappropriate. New lesions, increasing symptoms, continued close-contact exposure or signs of secondary skin infection warrant reassessment. The distinction between post-treatment symptoms and active infestation can matter as much as the initial choice of ivermectin or permethrin.
In the United States, both the human oral ivermectin tablets discussed here and permethrin cream 5% require a prescription. For oral ivermectin prescribed for scabies, the pharmacy processes a prescription for a medicine being used off-label; that does not erase the requirement for an authentic prescription or appropriate dispensing. For permethrin, the product description should identify cream 5% rather than a 1% head-lice product. Patients can ask whether the pharmacy has received the prescription, whether a generic product is being dispensed and whether the product identity and instructions match the prescriber’s order.
Price and insurance comparisons should be made using the exact medicine, formulation, quantity and payment method stated on the prescription. A plan may handle the two medicines or particular indications differently, and a cash quotation is not the same as an adjudicated insurance claim. No specific pharmacy stock, price, shipping window or reimbursement can be inferred from this comparison. The oral ivermectin cost guide and insurance coverage guide explain the related cost and benefits checks without publishing fragile price quotes.
For legitimate prescription fulfillment, readers can review the oral ivermectin purchase process or local pharmacy pickup and verification. Those pages cover general purchasing mechanics; this page stays focused on how the two scabies medicines differ. A licensed pharmacy can verify a product and clarify dispensing questions, but it cannot guarantee that a medicine is suitable for a particular patient solely because a prescription appears in a listing.
| What to verify | Why it matters for scabies | Who can confirm |
|---|---|---|
| Exact medicine | Oral ivermectin tablets versus permethrin cream 5% are distinct prescriptions | Prescriber and dispensing pharmacist |
| Correct condition | Scabies-specific assessment distinguishes classic from crusted presentations | Treating clinician |
| FDA status | Permethrin 5% is labeled for scabies; oral ivermectin use for scabies is off-label | Official product label and clinician |
| Product form and strength | Permethrin 5% cream is not a 1% lice product; tablet strengths do not set a regimen | Pharmacist |
| Instructions and follow-up | Application, oral administration and any repeat treatment differ | Prescriber and pharmacist |
| Allergies and other medicines | Product-specific cautions and possible drug interactions can change suitability | Clinician and pharmacist |
| Pharmacy and payment | A valid prescription, actual stock, coverage and cash price are separate questions | Licensed dispensing pharmacy and insurer |
| Symptoms or exposure after treatment | Persistent itching and new infestation require different responses | Treating clinician |
There is no universal winner. CDC guidance describes oral ivermectin and topical permethrin 5% as having similar effectiveness for classic scabies under studied conditions. A clinician considers the diagnosis, age, health history, practical application needs and product-specific safety factors before choosing an approach. Neither a product listing nor a comparison page can establish the best option for an individual.
No. Oral ivermectin tablets are FDA-approved for certain parasitic worm infections, while treatment of scabies is an off-label use. CDC includes oral ivermectin in clinical guidance for scabies, but that guidance does not change FDA labeling or remove the need for a legitimate prescription.
Yes. Permethrin cream 5% is FDA-approved for treating scabies and is available by prescription in the United States. It is a different product from lower-strength permethrin 1% preparations used for head lice. The specific prescription label and clinician instructions govern its use.
Both products in this comparison are prescription medicines in the United States. The availability of over-the-counter lice products does not make oral ivermectin tablets or permethrin 5% scabies cream nonprescription. A licensed pharmacy should require an appropriate prescription before dispensing either Rx product.
No. Permethrin 1% lice treatments and prescription permethrin cream 5% are different formulations with different labeled uses. The lower-strength product should not be treated as an equivalent scabies prescription because the active ingredient name happens to match.
No. OTC ivermectin lotion 0.5% is labeled for head lice and prescription ivermectin cream 1% is labeled for inflammatory lesions of rosacea. Neither should be assumed interchangeable with oral ivermectin used off-label for scabies. A clinician should evaluate the suspected infestation and the appropriate treatment.
Not always in the same way. The need for and timing of any repeat application or oral dose depend on the medicine, diagnosis and prescribed regimen. CDC discusses repeat treatment considerations for both options, but patients should follow their own clinician’s directions rather than copying a schedule from a website.
Permethrin cream 5% has an FDA-labeled scabies indication beginning at 2 months of age. CDC notes that safety of oral ivermectin for scabies has not been established in children weighing less than 15 kg or pregnant women. Pregnancy, breastfeeding and pediatric treatment require individualized clinical assessment, not a general substitution rule.
Not necessarily. Itching may persist after mites have been eliminated because the skin remains inflamed. New lesions, worsening symptoms or ongoing exposure may call for re-evaluation, but itching alone is not proof that additional medication is needed. A clinician can distinguish expected recovery from reinfestation or another cause.
No. Crusted scabies is a severe presentation that often requires specialist-guided treatment combining systemic and topical medicines plus measures to address contagiousness and close contacts. The simple comparison of oral ivermectin and permethrin cream for classic scabies does not substitute for a crusted-scabies management plan.